NASDAQ:DEPO - Depomed Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$8.14 -0.03 (-0.37 %)
(As of 07/20/2018 04:00 PM ET)
Previous Close$8.14
Today's Range$8.1050 - $8.26
52-Week Range$4.31 - $10.97
Volume473,319 shs
Average Volume1.45 million shs
Market Capitalization$519.51 million
P/E Ratio-6.46
Dividend YieldN/A
Depomed logoDepomed, Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; and Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults. The company also provides NUCYNTA ER (tapentadol extended release tablet), a product for the management of pain severe enough to long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults; and NUCYNTA IR (tapentadol), a product for the management of moderate to severe acute pain in adults. In addition, it is involved in the clinical development of Cebranopadol for the treatment of chronic nociceptive and neuropathic pain. Depomed, Inc. has a collaboration and license agreement with Ironwood Pharmaceuticals, Inc.; and a license agreement with Janssen Pharmaceuticals, Inc. based on its proprietary Acuform gastroretentive drug delivery technology. The company sells its products to wholesalers and retail pharmacies. Depomed, Inc. was founded in 1995 and is headquartered in Newark, California.

Receive DEPO News and Ratings via Email

Sign-up to receive the latest news and ratings for DEPO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity Ratio2.55
Current Ratio0.75
Quick Ratio0.73


Trailing P/E Ratio-6.46
Forward P/E Ratio-16.96
P/E GrowthN/A

Sales & Book Value

Annual Sales$380.72 million
Price / Sales1.36
Cash Flow$0.8332 per share
Price / Cash9.77
Book Value$2.69 per share
Price / Book3.03


EPS (Most Recent Fiscal Year)($1.26)
Net Income$-102,490,000.00
Net Margins-10.02%
Return on Equity-15.74%
Return on Assets-2.95%


Outstanding Shares63,590,000
Market Cap$519.51

Depomed (NASDAQ:DEPO) Frequently Asked Questions

What is Depomed's stock symbol?

Depomed trades on the NASDAQ under the ticker symbol "DEPO."

How were Depomed's earnings last quarter?

Depomed Inc (NASDAQ:DEPO) posted its quarterly earnings data on Thursday, May, 10th. The specialty pharmaceutical company reported $0.28 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.41) by $0.69. The specialty pharmaceutical company had revenue of $128.40 million for the quarter, compared to analyst estimates of $65.77 million. Depomed had a negative net margin of 10.02% and a negative return on equity of 15.74%. The business's quarterly revenue was up 41.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.07 earnings per share. View Depomed's Earnings History.

When is Depomed's next earnings date?

Depomed is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Depomed.

What price target have analysts set for DEPO?

7 equities research analysts have issued 1-year target prices for Depomed's stock. Their predictions range from $5.00 to $10.00. On average, they anticipate Depomed's share price to reach $8.2857 in the next twelve months. This suggests a possible upside of 1.8% from the stock's current price. View Analyst Ratings for Depomed.

What is the consensus analysts' recommendation for Depomed?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Depomed in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

Who are some of Depomed's key competitors?

Who are Depomed's key executives?

Depomed's management team includes the folowing people:
  • Mr. Arthur Joseph Higgins, CEO, Pres & Director (Age 62)
  • Mr. August J. Moretti, CFO & Sr. VP (Age 67)
  • Mr. Sean P. McKercher, Sr. VP of Operations & Bus. (Age 61)
  • Dr. Stan Bukofzer, Sr. VP and Chief Medical & Scientific Officer (Age 62)
  • Mr. John B. Thomas, Sr. VP of IR & Corp. Communications (Age 54)

Has Depomed been receiving favorable news coverage?

Headlines about DEPO stock have trended somewhat positive this week, Accern reports. Accern rates the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Depomed earned a daily sentiment score of 0.10 on Accern's scale. They also gave news coverage about the specialty pharmaceutical company an impact score of 50.51 out of 100, meaning that recent news coverage is somewhat likely to have an impact on the company's share price in the near term.

Who are Depomed's major shareholders?

Depomed's stock is owned by a variety of of retail and institutional investors. Top institutional investors include STARBOARD VALUE LP (6.10%), STARBOARD VALUE LP (4.30%), Bank of Montreal Can (0.55%), Campbell & CO Investment Adviser LLC (0.07%), Fox Run Management L.L.C. (0.03%) and Municipal Employees Retirement System of Michigan (0.03%). Company insiders that own Depomed stock include Arthur J Higgins, August J Moretti, Matthew M Gosling and Thadd M Vargas. View Institutional Ownership Trends for Depomed.

Which institutional investors are selling Depomed stock?

DEPO stock was sold by a variety of institutional investors in the last quarter, including Municipal Employees Retirement System of Michigan. View Insider Buying and Selling for Depomed.

Which institutional investors are buying Depomed stock?

DEPO stock was bought by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Campbell & CO Investment Adviser LLC and Fox Run Management L.L.C.. View Insider Buying and Selling for Depomed.

How do I buy shares of Depomed?

Shares of DEPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Depomed's stock price today?

One share of DEPO stock can currently be purchased for approximately $8.14.

How big of a company is Depomed?

Depomed has a market capitalization of $519.51 million and generates $380.72 million in revenue each year. The specialty pharmaceutical company earns $-102,490,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. Depomed employs 434 workers across the globe.

How can I contact Depomed?

Depomed's mailing address is 7999 GATEWAY BLVD. SUITE 300, NEWARK CA, 94560. The specialty pharmaceutical company can be reached via phone at 510-744-8000 or via email at [email protected]

MarketBeat Community Rating for Depomed (NASDAQ DEPO)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  434 (Vote Outperform)
Underperform Votes:  321 (Vote Underperform)
Total Votes:  755
MarketBeat's community ratings are surveys of what our community members think about Depomed and other stocks. Vote "Outperform" if you believe DEPO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DEPO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/21/2018 by Staff

Featured Article: Earnings Per Share

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.